 CAMBRIDGE, Mass., Nov. 02, 2021 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that scientific posters sharing preclinical data will be presented at the Society for Immunotherapy of Cancer SITC 2021 Annual Meeting, to be held virtually and at the Walter E. Washington Convention Center in Washington, D.C. November 10-14, 2021. 